(Fargo, ND) Aldevron announced the completion of a 4,500-square-foot expansion of its GMP and GMP-Source™ biological manufacturing facilities in Fargo, North Dakota. The project increases the company’s available production capacity by over 35%. This expansion is in response to increasing demand for Aldevron’s custom plasmid, therapeutic RNA transcript, and enzyme services, and affirms the Company's position as a global leader in contract manufacturing for the biopharmaceutical industry. Aldevron’s products are used in a wide array of gene therapy, gene editing, and immunotherapy programs.

Aldevron’s operations began in a laboratory at North Dakota State University in 1998 and have grown to include sites in Fargo, Madison, Wisconsin, and Freiburg, Germany. The Fargo site currently employs over 100 people and the company expects to increase its headcount to 130 by the end of 2016.